ANIK — Q2 2026 Financial Report Analysis

Anika swings to a $3.3 million profit as J&J volumes and cost cuts lift margins

Anika Therapeutics makes hyaluronic acid (HA) products, mostly knee injections that ease osteoarthritis pain, plus implants used in tendon and cartilage repair. In the second quarter of 2026 (April–June), revenue rose 16% to $32.6 million and the company earned $3.3 million, against a $4.0 million loss a year earlier. Two things did most of the work: Johnson & Johnson's orthopedics business (J&J MedTech), which sells Anika's Monovisc and Orthovisc injections in the US, bought far more units, and Anika cut general and administrative staff early in the year. Management raised its full-year profit outlook but also said the second half will be weaker, because part of the first half's strength came from the timing of J&J orders.

At a glance

• Gross margin of 65%, up from 51%. Gross margin is the share of revenue left after the cost of making the products. Busier factories spread fixed costs over more units, so each injection cost less to make.
• Commercial Channel revenue of $13.9 million, up 17%. This is the business Anika sells under its own brand, rather than through partners. It is the part management is trying to grow, and this was its best quarter on record.
• Cash fell from $57.5 million to $38.4 million in six months. The company spent $9.5 million buying back its own shares, and day-to-day operations used another $5.5 million of cash because inventory built up.

Results summary

Operating margin is the share of revenue left after running the business (making products, research, sales and overhead), before interest and tax. The prior-year net loss includes a $0.7 million gain from discontinued operations (businesses Anika has since sold); on continuing operations alone, the year-ago loss was $4.6 million, or $0.33 per share.

For the first half (January–June), revenue was $62.2 million, up 14%, and the company still lost $1.7 million, because the first quarter carried $1.6 million of severance and a stock-compensation charge tied to the former CEO's departure.

What drove the quarter

OEM Channel: more units at lower prices. OEM means "original equipment manufacturer": Anika makes the product and a partner sells it under the partner's name. According to the 10-Q, J&J MedTech revenue rose $3.2 million, made up of a $6.1 million increase from higher volume and a $2.9 million decrease from lower pricing. Non-orthopedic sales (mainly veterinary products) fell $0.9 million because of shipment timing. So Anika is selling more injections to J&J at lower prices per unit. Management also said the second half will slow because some J&J orders came earlier than usual.

Commercial Channel: growth was mostly international. Of the $2.0 million increase, $1.6 million came from international sales of OA pain products (Cingal and Monovisc), and $0.4 million from regenerative products (Integrity and Hyalofast). Anika said international revenue was a record $12.6 million, up 22%. In the US, Integrity, a scaffold used in rotator-cuff and tendon repair, is the main growth product. The company said its sales so far this year are up 39%, but it does not report the dollar amount.

Costs: lower overhead, higher R&D. Selling, general and administrative expenses fell to $10.9 million from $12.2 million, which the 10-Q puts down to "reduced headcount with severance actions announced in the first quarter of 2026 and lower legal fees." This quarter still included $0.8 million of severance. Research and development rose 16% to $7.3 million, mostly for the Cingal drug study.

What the headline numbers hide

• Profit has not turned into cash yet. Operations used $5.5 million of cash in the first half, compared with $0.3 million a year earlier. Inventory (on the balance sheet, current portion) rose 52% to $28.6 million since December, while first-half revenue rose 14%. Receivables (money customers owe) rose 23% to $29.1 million. The 10-Q says the inventory came from higher production and "building up safety stock." That supports the higher gross margin, since more production lowers the cost per unit, but it ties up cash. If production slows in the second half when OEM orders ease, some of the margin gain may reverse.
• Part of the gross margin gain is about timing. The 10-Q credits higher volume, more production and a richer mix from J&J sales. Management has said the J&J order timing will partly reverse, so 65% should not be read as the new normal margin.
• The adjusted figures are much higher than GAAP. GAAP is the standard accounting rulebook. Adjusted net income of $5.9 million ($0.42 per share) is $2.6 million above GAAP net income because it excludes $1.8 million of stock-based compensation and $0.8 million of severance, both after tax. Stock-based compensation is a real and recurring cost of paying staff. For the first half, the company's "tax-effected" stock-compensation add-back ($10.3 million) is larger than the pre-tax expense ($8.5 million). That is unusual and makes the half-year adjusted EPS of $0.86 harder to rely on.
• Tax was close to zero. Income tax was $0.1 million on $3.4 million of pre-tax income, an effective tax rate of 2.1%. That is because of a full valuation allowance on US deferred tax assets: in plain terms, past losses have built up tax credits, and the accounts do not count them as assets yet. The low rate added to this quarter's profit and should not be assumed to continue.
• Buybacks shrank the share count but are now finished. Diluted shares fell to 13.7 million from 14.5 million (−5.5%). Because the prior year was a loss, this did not create the swing to profit, but it does raise future per-share figures. Anika finished its $15 million Clear Street repurchase in April 2026 and says it is "no longer actively repurchasing stock." That removes the largest cash outflow of the first half.
• Liquidity. On July 10, 2026 Anika amended its Bank of America revolving credit line: $50 million, with an option to request up to $50 million more, maturing in 2031. The 10-Q does not show any borrowing under it, so it serves as a backstop while cash is lower.

Takeaway: This quarter's profit came from J&J ordering more units, which filled the factory and lifted gross margin to 65%, and from lower overhead. Management already expects the J&J order timing to partly reverse in the second half. The more durable sign is the 17% growth in Anika's own Commercial Channel. The swing to profit has not yet shown up as cash: inventory grew much faster than sales.

Outlook

Management raised its 2026 guidance:

First-half revenue grew 14%, so the full-year range of 5% to 10% implies the second half grows more slowly than the first, or even shrinks. The CEO said this directly: "we expect some moderation in revenue and profitability during the second half relative to the strong first half, reflecting the timing of certain OEM orders." The first-half adjusted EBITDA margin was about 18% ($11.4 million on $62.2 million). The full-year range of 13% to 17% implies a lower margin in the second half.

Anika also changed how it guides. From now on, its forecasts only include products that already have regulatory approval. As a result, it cut its 2027 Commercial Channel growth forecast to 5% to 15% (from 10% to 20%) and now expects total 2027 revenue to range from flat to up 5%. The main reason is Hyalofast, a cartilage-repair product sold outside the US. The US application filed in October 2025 received an FDA deficiency letter in January 2026, and talks are now about the trial's main success measures. Cingal, an injection that combines HA with a steroid, is still in a bioequivalence study and manufacturing work before a drug application can be filed. Neither product has a US approval date.

What to watch in Q3: how far OEM revenue falls back, and whether gross margin stays in the 60s once production eases; whether inventory and receivables start turning into cash now that buybacks have stopped; and any FDA progress on Hyalofast, which is now outside the guidance.